Quantcast

Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019

̶ Presentation to be webcast on www.exelixis.com
̶

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ: EXEL) today announced that Christopher J.
Senner, the company’s Executive Vice President and Chief Financial
Officer, and Andrew R. Peters, the company’s Vice President, Strategy,
will provide an overview of the company at the 18th Annual
Needham Healthcare Conference taking place on Wednesday, April 10, 2019
in New York, NY. The Exelixis presentation is scheduled that day for
4:10 PM EDT / 1:10 PM PDT.

To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the webcast. A
replay will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. Our discovery efforts
have resulted in four approved products, CABOMETYX®
(cabozantinib), COMETRIQ® (cabozantinib), COTELLIC®
(cobimetinib) and MINNEBRO™ (esaxerenone), and we have entered into
partnerships with leading pharmaceutical companies to bring these
important medicines to patients worldwide. Supported by revenues from
our marketed products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our pipeline.
We are supplementing our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis is a member of Standard &
Poor’s (S&P) MidCap 400 index, which measures the performance of
profitable mid-sized companies. For more information about Exelixis,
please visit www.exelixis.com,
follow @ExelixisInc
on Twitter or like Exelixis,
Inc.
on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks. MINNEBRO is a Japanese trademark.

Contacts

Investors Contact:
Susan Hubbard
EVP, Public
Affairs and Investor Relations

Exelixis, Inc.
650-837-8194
[email protected]

Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
[email protected]

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.